Biosimilars have the potential to lower the high costs of biologic treatments for patients suffering from chronic skin diseases. Although biosimilars have received FDA approval derms still have many questions about what they are and when they may be used appropriately. Patent wars and a lack of rules and regulations at the state level add to the confusion about using biosimilars.
Laser and light source treatments target many of the most common skin conditions that dermatologists encounter. The recent expansion in laser dermatology is both promising and exciting as the treatments available to derms and their patients continue to grow. New technologies are taking laser and light source treatments in new directions of skin structure imaging, epidermal harvesting, tissue rejuvenation, and new types of photodynamic therapies.
It is important to note that where there are two or more recognized methods of diagnosing or treating the same condition, a physician does not fall below the standard of care by using any of the acceptable methods even if one method turns out to be less effective than another method.
Dr. Mark Lebwohl talks about the FDA’s approval of the anti-interleukin-17 receptor monoclonal antibody brodalumab (Siliq, Valeant Pharmaceuticals) for treatment of adults with moderate-to-severe plaque psoriasis.